Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight …
M Schou, B Claggett, ZM Miao… - European Journal of …, 2024 - Wiley Online Library
Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight …
M Schou, B Claggett, ZM Miao… - European Journal of …, 2023 - research.regionh.dk
AIM: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight …
M Schou, B Claggett, ZM Miao… - European Journal of …, 2024 - research.rug.nl
Aim: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: insight from …
M Schou, B Claggett, A Fernandez, G Filippatos… - researchgate.net
Background: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of
cardiovascular death or heart failure admission in patients with myocardial infarction (MI) …
cardiovascular death or heart failure admission in patients with myocardial infarction (MI) …
Sacubitril/valsartan compared to ramipril in high-risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from …
M Schou, B Claggett, ZM Miao… - European Journal of …, 2023 - europepmc.org
Background It is unknown whether safety and clinical endpoints by use of
sacubitril/valsartan (ARNI) is affected by Mineralocorticoid receptor antagonists (MRA) in …
sacubitril/valsartan (ARNI) is affected by Mineralocorticoid receptor antagonists (MRA) in …
Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight …
M Schou, B Claggett, ZM Miao… - European Journal of …, 2023 - eprints.gla.ac.uk
Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight …
M Schou, B Claggett, ZM Miao… - European journal of … - pubmed.ncbi.nlm.nih.gov
Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …
angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …